Disease Cell Targeted Precision Medicine

Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation.

Welcome to Ashvattha

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel precision nanomedicines enabled by our hydroxyl dendrimer (HD) technology to treat unmet medical needs in ophthalmology, neurology, and inflammatory diseases. Our precision nanomedicines are selectively taken up only by inflamed tissues, allowing us to treat disease with unprecedented precision.

Jeffrey Cleland, Ph.D., Ashvattha Chairman, CEO and President interview with Health Professional Radio, July 1, 2021

"Potential COVID Treatments That Address Brain Inflammation"

We have designed a potent anti-angiogenic nanomedicine that crosses the blood-retinal barrier and selectively targets activated microglia, macrophages, and retinal pigment epithelial cells in the eye

We are developing a biomarker for neuroinflammation to quantitatively study penetration of the blood-brain barrier and measure treatment responses to our nanomedicines

Our novel nanomedicine selectively targets regions of inflammation and has the potential to modulate the activity of cells that direct inflammation in multiple diseases

Pipeline Updated May 25 2023

Latest News